Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography
- 1 January 1990
- journal article
- research article
- Published by Elsevier in Journal of Chromatography B: Biomedical Sciences and Applications
- Vol. 528 (2) , 385-394
- https://doi.org/10.1016/s0378-4347(00)82396-8
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- PHASE-I TRIAL OF THE AMSACRINE ANALOG 9-((2-METHOXY-4-[(METHYLSULFONYL)AMINO]-PHENYL(AMINO)-N,5-DIMETHYL-4-ACRIDINECARBOXAMIDE (CI-921)1988
- Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4-acridinecarboxamide (CI-921) in rabbitsCancer Chemotherapy and Pharmacology, 1987
- Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamideJournal of Medicinal Chemistry, 1987
- Elimination Kinetics of Amsacrine in the Rabbit: Evidence of NonlinearityPharmacology, 1985
- SYNTHESIS, ANTITUMOR-ACTIVITY, AND DNA-BINDING PROPERTIES OF A NEW DERIVATIVE OF AMSACRINE, N-5-DIMETHYL-9-[(2-METHOXY-4-METHYLSULFONYLAMINO)PHENYLAMINO]-4-ACRIDINECARBOXAMIDE1984
- High-performance liquid chromatographic method for the determination of 4′-(9-acridinylamino)methanesulfon-m-anisidide in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1983